Thrombotic microangiopathy: Differential diagnosis, pathophysiology and therapeutic strategies

Mount Sinai Journal of Medicine

Volumn 72, Issue 3, 2005, Pages 166-175

  Mayer, Sebastian A ^a   Aledort, Louis M ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

ADAMTS 13; Hemolytic uremic syndrome; Plasma exchange; Thrombotic microangiopathy; Thrombotic thrombocytopenic purpura; von Willebrand factor

Indexed keywords

AZATHIOPRINE; BACTERIAL TOXIN; CARBOPLATIN; CISPLATIN; CLOPIDOGREL; COMPLEMENT FACTOR H; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FRESH FROZEN PLASMA; GEMCITABINE; IMMUNOGLOBULIN; LACTATE DEHYDROGENASE; MITOMYCIN C; PREDNISONE; QUININE; RITUXIMAB; SHIGA TOXIN; TACROLIMUS; TICLOPIDINE; VINCRISTINE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

AUTOIMMUNE DISEASE; BONE MARROW TRANSPLANTATION; BREAST ADENOCARCINOMA; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DIGESTIVE SYSTEM CANCER; ENDOTHELIUM LESION; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IDIOPATHIC DISEASE; IMMUNOADSORPTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG ADENOCARCINOMA; PATHOPHYSIOLOGY; PLASMA TRANSFUSION; PLASMAPHERESIS; PROSTATE ADENOCARCINOMA; REVIEW; SHEAR STRESS; STANDARDIZATION; STEM CELL TRANSPLANTATION; THROMBOTIC THROMBOCYTOPENIC PURPURA;

DIAGNOSIS, DIFFERENTIAL; HEMOLYTIC-UREMIC SYNDROME; HUMANS; PROGNOSIS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; THROMBOCYTOPENIA; THROMBOSIS; VON WILLEBRAND FACTOR;

EID: 18744397209     PISSN: 00272507     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (132)

1. Symmers W. Thrombotic microangiopathic hemolytic anemia (thrombotic microangiopathy). Br Med J 1952; 2:897-903.
2. Remuzzi G, Ruggenenti P, Bertani T. Thrombotic microangiopathies. In: Tisher CC, Brenner BM, editors. Renal pathology: with clinical and functional correlations. Philadelphia: JB Lippincott Company; 1994. p. 1154.
3. Moschcowitz E. An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries. Arch Intern Med 1925; 36(1):89-93.
4. Gasser C, Gautier E, Steck A, et al. Haemolytisch-uraemisches Syndrom bilateraler Nierenrindennekrosen bei akuten erworbenen haemolytischen Anaemien [German]. Schweiz Med Wschr 1955; 85(38-39):905-909.
5. Miller DP, Kaye JA, Shea K, et al. Incidence of thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome. Epidemiology 2004; 15(2):208-215.
6. Moake JL, Chow TW. Thrombotic thrombocytopenic purpura: understanding a disease no longer rare. Am J Med Sci 1998; 316(2):105-119.
7. Vipan WH. Quinine as cause of purpura. Lancet 1865; 2:37.
8. Kojouri K, Vesely SK, George JN. Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: frequency, clinical features, and long-term outcomes. Ann Intern Med 2001; 135(12): 1047-1051.
9. del Zoppo GJ. Antiplatelet therapy in thrombotic thrombocytopenic purpura. Semin Hematol 1987; 24(2):130-139.
10. Page Y, Tardy B, Zeni F, et al. Thrombotic thrombocytopenic purpura related to ticlopidine. Lancet 1991; 337(8744):774-776.
11. SoRelle R. Clopidogrel-associated thrombotic thrombocytopenic purpura identified. Circulation 2000; 101(18):E9036-E9037.
12. Walfe JA, McCann RL, Sanfilippo F. Cyclosporine-associated microangiopathy in renal transplantation: a severe, potentially reversible form of early graft injury. Transplantation 1986; 41(4):541-544.
13. Dzik WH, Georgi BA, Khettry U, et al. Cyclosporine-associated thrombotic thrombocytopenic purpura following liver transplantation - successful treatment with plasma exchange. Transplantation 1987; 44(4):570-572.
14. Holman MJ, Gonwa TA, Cooper B, et al. FK506-associated thrombotic thrombocytopenic purpura. Transplantation 1993; 55(1):205-206.
15. Trimarchi HM, Truong LD, Brennan S, et al. FK506-associated thrombotic microangiopathy: report of two cases and review of the literature. Transplantation 1999; 67(4):539-544.
16. Bayle F, Vialtel P, Bastrenta F, et al. Thrombotic microangiopathy and chronic renal failure caused by mitomycin C in 4 women treated for breast cancer [French]. Nouv Presse Med 1982; 11(30):2300-2301.
17. Humphreys BD, Sharman JP, Henderson JM, et al. Gemcitabine-associated thrombotic microangiopathy. Cancer 2004; 100(12):2664-2670.
18. Blanche P, Wyplosz B, Herry I, Sicard D. Thrombotic microangiopathy after chemo-embolization with cisplatin [French]. Ann Med Interne (Paris) 1995; 146(6):452.
19. Khansur T, Kennedy A. Case report: cisplatin-induced hemolytic uremic syndrome. Am J Med Sci 1991; 301(6):390-392.
20. Walker RW, Rosenblum MK, Kempin SJ, Christian MC. Carboplatin-associated thrombotic microangiopathic hemolytic anemia. Cancer 1989; 64(5):1017-1020.
21. Laffay DL, Tubbs RR, Valenzuela R, et al. Chronic glomerular microangiopathy and metastatic cancer. Hum Pathol 1979; 10(4):433-438.
22. Chang JC, Naqvi T. Thrombotic thrombocytopenic purpura associated with bone marrow metastasis and secondary myelofibrosis in cancer. Oncologist 2003; 8(4):375-380.
23. Thompson CE, Damon LE, Ries CA, Linker CA. Thrombotic microangiopathies in the 1980s: clinical features, response to treatment, and the impact of the human immunodeficiency virus epidemic. Blood 1992; 80(8):1890-1895.
24. Weiner NJ, Goodman JW, Kimmel PL. The HIV-related renal diseases: current insight into pathogens and treatment. Kidney Int 2003; 63(5):1618-1631.
25. Alpers CE. Light at the end of the TUNEL: HIV-associated thrombotic microangiopathy. Kidney Int 2003; 63(1):385-396.
26. Dekker A, O'Brien ME, Cammarata RJ. The association of thrombotic thrombocytopenic purpura with systemic lupus erythematosus. Am J Med Sci 1974; 267:243-249.
27. Nesher G, Hanna VE, Moore TL, et al. Thrombotic microangiopathic hemolytic anemia in systemic lupus erythematosus. Semin Arthritis Rheum 1994; 24(3):165-172.
28. Daily WM, Morey DA, White JB. Thrombotic thrombocytopenic purpura diagnosed by random lymph node biopsy. AMA Arch Intern Med 1956; 98(6):821-823.
29. Steinberg AD, Green WT, Talal N. thrombotic thrombocytopenic purpura complicating Sjogren's syndrome. JAMA 1971; 215:757-761.
30. Benitez L, Mathews M, Mallory GK. Platelet thrombosis with polyarteritis nodosa: report of a case. Arch Pathol 1964; 77:116-125.
31. McLeod BC, Wu KK, Knospe WH. Plasmapheresis in thrombotic thrombocytopenic purpura. Arch Intern Med 1980; 140:1059-1060.
32. Myers TJ, Wakem CJ, Ball ED, Tremont SJ. Thrombotic thrombocytopenic purpura: combined treatment with plasmapheresis and antiplatelet agents. Ann Intern Med 1980; 92(2 Pt 1):149-155.
33. Pettitt AR, Clark RE. Thrombotic microangiopathy following bone marrow transplantation. Bone Marrow Transplant 1994; 14(4):495-504.
34. Iacopino P, Pucci G, Arcese W, et al. Severe thrombotic microangiopathy: an infrequent complication of bone marrow transplantation. Gruppo Italiano Trapianto Midollo Osseo (GITMO). Bone Marrow Transplant 1999; 24(1):47-51.
35. Fuge R, Bird JM, Fraser A, et al. The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation. Br J Haematol 2001;113(1):58-64.
36. McCrae KR, Cines DB. Thrombotic microangiopathy during pregnancy. Sem Hematol 1997; 34:148-158.
37. Esplin MS, Branch DW. Diagnosis and management of thrombotic microangiopathies during pregnancy. Clin Obstet Gynecol 1999; 42:360-367.
38. Brostrom S, Bergmann OJ. Thrombotic thrombocytopenic purpura: a difficult diagnosis in pregnancy. Acta Obstet Gynecol Scand 2000; 79(1):84-85. a difficult diagnosis in pregnancy. Acta Obstet Gynecol Scand 2000; 79(1):84-85.
39. Karmali MA, Petric M, Lim C, et al. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis 1985; 151(5):775-782.
40. Boyce TG, Swerdlow DL, Griffin PM. Escherichia coli O157:H7 and the hemolytic-uremic syndrome. N Engl J Med 1995; 333(6):364-368.
41. Pichette V, Querin S, Schurch W, et al. Familial hemolytic-uremic syndrome and homozygous factor H deficiency. Am J Kidney Dis 1994; 24(6):936-941.
42. Warwicker P, Goodship TH, Donne RL, et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 1998; 53(4):836-844.
43. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339(22):1578-1584.
44. Tsai HM, Lian E. Antibodies to von Willebrand cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339:1585-1594.
45. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Group. N Engl J Med 1991; 325:393-397.
46. Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-emolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 1991; 325(6):398-402.
47. Cohen JA, Brecher ME, Bandarenko N. Cellular source of serum lactate dehydrogenase in patients with thrombotic thrombocytopenic purpura. J Clin Apheresis 1998; 13(1):16-19.
48. Moake JL. Haemolytic uraemic syndrome: basic science. Lancet 1994; 343:393-397.
49. Marder VJ, Martin SE, Francis CW, Colman RW. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, editors. Consumptive thrombo-hemorrhagic disorders. In: Hemostasis and thrombosis: basic principles and clinical practice. 2nd ed. Philadelphia: Lippincott; 1987. pp. 975-1015.
50. Robboy SJ, Salisbury K, Ragsdale B, et al. Mechanism of Aspergillus-induced microangiopathic hemolytic anemia. Arch Intern Med 1971; 128(5):790-793.
51. Jeejeebhoy FM, Zaltzman JS. Thrombotic microangiopathy in association with cytomegalovirus infection in a renal transplant patient: a new treatment strategy. Transplantation 1998; 65(12):1645-1648.
52. Cerveny KC, Sawitzke AD. Relapsing catastrophic antiphospholipid antibody syndrome: a mimic for thrombotic thrombocytopenic purpura? Lupus 1999; 8(6):477-481.
53. Espinosa G, Bucciarelli S, Cervera R, et al. Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Ann Rev Rheum Dis 2004; 63(6):730-736.
54. Capelli JP, Wesson GL Jr, Erslev AV. Malignant hypertension and red cell fragmentation syndrome - report of a case. Ann Intern Med 1966; 64(1):128-136.
55. Khanna A, McCullough PA. Malignant hypertension presenting as hemolysis, thrombocytopenia, and renal failure. Rev Cardiovasc Med 2003; 4(4):255-259.
56. McCrae KR, Samuels P, Schreiber AD. Pregnancy-associated thrombocytopenia: pathogenesis and management. Blood 1992; 80(11):2697-2710.
57. Ross CN, Reuter H, Scott D, Hamilton DV. Microangiopathic haemolytic anemia and systemic vasculitis. Br J Rheumatol 1996; 35(4):377-379.
58. Baehr G, Klemperer P, Schifrin A. An acute febrile anemia with thrombocytopenic purpura with diffuse platelet thrombosis of capillaries and arterioles. Trans Assoc Am Physicians 1936; 65:43-58.
59. Brain MC, Dacie JV, Hourihane DO. Microangiopathic hemolytic anemia: the possible role for vascular lesions in pathogenesis. Br J Haematol 1962; 8:358-374.
60. Rubenberg ML, Bull BS, Regoeczi E, et al. Experimental production of microangiopathic haemolytic anaemia in vivo. Lancet 1967; 2(7526):1121-1123.
61. Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982; 307(23):1432-1435.
62. Ruggeri ZM. Structure and biosynthesis of von Willebrand factor. In: Ruggeri ZM, editor. von Willebrand factor and the mechanisms of platelet function. Berlin: Springer; 1998. pp. 33-77.
63. Fowler WE, Fretto LJ. Electron microscopy of von Willebrand Factor. In: Zimmerman TS, Ruggeri ZM, editors. Coagulation and bleeding disorders: the role of factor VIII and von Willebrand factor. 1st ed. New York: Marcel Dekker; 1989. pp. 181-193.
64. Kao KJ, Pizzo SV, McKee PA. Platelet receptors for human factor VIII/von Willebrand protein: functional correlation of receptor occupancy and ristocetin-induced platelet aggregation. Proc Natl Acad Sci USA 1979; 76(10):5317-5320.
65. Weiss HJ, Sussman II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. J Clin Invest 1977; 60(2):390-404.
66. Arya M, Anvari B, Romo GM, et al. Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers. Blood 2002; 99:3971-3977.
67. Moake JL, Turner NA, Stathopoulos NA, et al. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest 1986; 78(6):1456-1461.
68. Moake JL, Turner NA, Stathopoulos NA, et al. Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin. Blood 1988; 71(5):1366-1374.
69. Alevriadou BR, Moake JL, Turner NA, et al. Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets. Blood 1993; 81(5):1263-1276.
70. Siedlecki CA, Lestini BJ, Kottke-Marchant KK, et al. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood 1996; 88(8):2939-2950.
71. Dong JF, Moake JL, Bernardo A, et al. ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor. J Biol Chem 2003; 278(32):29633-29639.
72. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87(10):4235-4244.
73. Furlan M, Robles R, Lamie B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87(10):4223-4234.
74. Furlan M, Robles R, Solenthaler M, et al. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997; 89(9):3097-3103.
75. Upshaw JD Jr. Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia. N Engl J Med 1978; 298(24):1350-1352.
76. Furlan M, Robles R, Solenthaler M, Lammle B. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood 1998; 91(8):2839-2846.
77. Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001; 98(6):1662-1666.
78. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413(6855):488-494.
79. Kokame K, Miyata T. Genetic defects leading to hereditary thrombotic thrombocytopenic purpura. Semin Hematol 2004; 41(1):34-40.
80. Moore JC, Hayward CP, Warkentin TE, Kelton JG. Decreased von Willebrand factor-cleaving protease activity associated with thrombocytopenic disorders. Blood 2001; 98(6):1842-1846.
81. Loof AH, van Vliet HH, Kappers-Klunne MC. Low activity of von Willebrand factor-cleaving protease is not restricted to patients suffering from thrombotic thrombocytopenic purpura [letter]. Br J Haematol 2001; 112(4):1087-1088.
82. Mannucci PM, Canciani MT, Forza I, et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001; 98(9):2730-2735.
83. Mannucci PM, Karimi M, Mosalaei A, et al. Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 (von Willebrand factor cleaving protease). Haematologica 2003; 88(4):454-458.
84. Bianchi V, Robles R, Alberio L, et al. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 2002; 100(2):710-713.
85. Vesely SK, George JN, Lammle B, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003; 102(1):60-68.
86. Tsai HM, Rice L, Sarode R, et al. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med 2000; 132(10):794-799.
87. Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000; 342(24):1773-1777.
88. van der Plas RM, Schiphorst ME, Huizinga EG, et al. von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura. Blood 1999; 93(11):3798-3802.
89. Brown Z, Neild GH, Willoughby JJ, et al. Increased factor VIII as an index of vascular injury in cyclosporine nephrotoxicity. Transplantation 1986; 42(2):150-153.
90. Carlsen E, Flatmark A, Prydz H. Cytokine-induced procoagulant activity in monocytes and endothelial cells. Further enhancement by cyclosporine. Transplantation 1988; 46(4):575-580.
91. van Ojik H, Biesma DH, Fijnheer R, et al. Cyclosporin for thrombotic thrombocytopenic purpura after autologous bone marrow transplantation. Br J Haematol 1997; 96(3):641-643.
92. Stroes ES, Lüscher TF, de Groot FG, et al. Cyclosporin A increases nitric oxide activity in vivo. Hypertension 1997; 29(2):570-575.
93. Hosler GA, Cucumano AM, Hutchins GM. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. Arch Pathol Lab 2003; 127(7):834-839.
94. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 2001; 60:831-846.
95. Rougier N, Kazatchkine MD, Rouger JP, et al. Human complement factor H deficiency associated with hemolytic uremic syndrome. J Am Soc Nephrol 1998; 9:2318-2326.
96. Konowalchuk J, Speirs JI, Stavric S. Vero response to a cytotoxin of Escherichia coli. Infect Immunol 1977; 18(3):775-779.
97. Arab S, Lingwood CA. Intracellular targeting of the endoplasmic reticulum/nuclear envelope by retrograde transport may determine cell hypersensitivity to verotoxin via globotriaosyl ceramide fatty acid isoform traffic. J Cell Physiol 1998; 177:646-660.
98. te Loo DM, Monnens LA, van Der Velden TJ, et al. Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome. Blood 2000; 95(11):3396-3402.
99. Andreoli SP. The pathophysiology of the hemolytic uremic syndrome. Curr Opin Nephrol Hypertens 1999; 8:459-464.
100. Moake JL, Byrnes JJ, Troll JH, et al. Abnormal VIII: von Willebrand factor patterns in the plasma of patients with the hemolytic-uremic syndrome. Blood 1984; 64(3):592-598.
101. Kaplan BS, Cleary TG, Obrig TG. Recent advances in understanding the pathogenesis of the hemolytic uremic syndromes. Pediatr Nephrol 1990; 4(3):276-283.
102. Zipfel PF, Hellwage J, Friese MA, et al. Factor H and disease: a complement regulator affects vital body functions. Mol Immunol 1999; 36(4-5):241-248.
103. Monnens L, Molenaar T, Lambert BH, et al. The complement system in hemolytic-uremic syndrome in childhood. Clin Nephrol 1980; 13(4):168-171.
104. Noris M, Ruggenenti P, Perna A, et al. Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. J Am Soc Nephrol 1999; 10(2):281-293.
105. Caprioli J, Bettinaglio P, Zipfel PF, et al. The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J Am Soc Nephrol 2001; 12(2):297-307.
106. Buddles MR, Donne RL, Richards A, et al. Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome. Am J Hum Genet 2000; 66(5):1721-1722.
107. Ying L, Katz Y, Schlesinger M, et al. Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome. Am J Hum Genet 1999; 65(6):1538-1546.
108. Byrnes JJ, Khurana M. Treatment of thrombotic thrombocytopenic purpura with plasma. N Engl J Med 1977; 297(25):1386-1389.
109. Byrnes JJ, Moake JL, Panpit K, Periman P. Effectiveness of the cryosupernatant fraction of plasma in the treatment of refractory thrombotic thrombocytopenic purpura. Am J Hematol 1990; 34:169-174.
110. Shumak KH, Rock GA, Nair R, Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Canadian Alpheresis Group. Ann Intern Med 1995; 122(8):569-572.
111. Chintagumpala MM, Hurwitz RL, Moake JL, et al. Chronic relapsing thrombotic thrombocytopenic purpura in infants with large von Willebrand factor multimers during remission. J Pediatr 1992; 120(1):49-53.
112. Moake J, Chintagumpala M, Turner N, et al. Solvent/detergent-treated plasma suppresses shear-induced platelet aggregation and prevents episodes of thrombotic thrombocytopenic purpura. Blood 1994; 84(2):490-497.
113. Allford SL, Bird JM, Marks DI. Thrombotic thrombocytopenic purpura following stem cell transplantation. Leuk Lymphoma 2002; 43: 1921-1926.
114. Daly AS, Xenocostas A, Lipton JH. Transplantation-associated thrombotic microangiopathy: twenty-two years later. Bone Marrow Transplant 2002; 30:709-715.
115. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 2004; 103(11):4043-4049.
116. George JN. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood 2000; 96(4):1223-1229.
117. Siegler RL. The hemolytic uremic syndrome. Pediatr Clin North Am 1995; 42(6):1505-1529.
118. Alessandrino EP, Martinelli G, Canevari A, et al. Prompt response to high-dose intravenous immunoglobulins given as first-line therapy in post-transplant thrombotic thrombocytopenic purpura. Bone Marrow Transplant 2000; 25(11):1217-1218.
119. Kondo H, Imamura T. Effects of intravenous immunoglobulin in a patient with intermittent thrombotic thrombocytopenic purpura. Br J Haematol 2000; 108(4):880-882.
120. Dervenoulas J, Tsirigotis P, Bollas G, et al. Efficacy of intravenous immunoglobulin in the treatment of thrombotic thrombocytopaenic purpura. A study of 44 cases. Acta Haematol 2001; 105(4):204-208.
121. Cuttner J. Splenectomy, steroids, and dextran 70 in thrombotic thrombocytopenic purpura. JAMA 1974; 227(4):397-402.
122. Onundarson PT, Rowe JM, Heal JM, Francis CW. Response to plasma exchange and splenectomy in thrombotic thrombocytopenic purpura. A 10-year experience at a single institution. Arch Intern Med 1992; 152(4):791-796.
123. Aqui NA, Stein SH, Konkle BA, et al. Role of splenectomy in patients with refractory or relapsed thrombotic thrombocytopenic purpura. J Clin Apheresis 2003; 18(2):51-54.
124. Gaddis TG, Guthrie TH Jr, Drew MJ, et al. Treatment of plasma refractory thrombotic thrombocytopenic purpura with protein A immunoabsorption. Am J Hematol 1997; 55(2):55-58.
125. Zappasodi P, Corso A, Castagnol C, et al. A successful combination of plasma exchange and intravenous cyclophosphamide in a patient with a refractory thrombotic thrombocytopenic purpura. Eur J Haematol 1999; 63(4):278-279.
126. Moake JL, Rudy CK, Troll CH. Therapy of chronic relapsing thrombotic thrombocytopenic purpura with prednisone and azathioprine. Am J Hematol 1985; 20(1):73-79.
127. Ferrara F, Annunziata M, Pollio F, et al. Vincristine as treatment for recurrent episodes of thrombotic thrombocytopenic purpura. Ann Hematol 2002; 81(1):7-10.
128. Ahmad A, Aggarwal A, Sharma D, et al. Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP). Am J Hematol 2004; 77(2):171-176.
129. Yomtovian R, Niklinski W, Silver B, et al. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Br J Haematol 2004; 124(6):787-795.
130. Tsai HM. Is severe deficiency of ADAMTS-13 specific for thrombotic thrombocytopenic purpura? Yes. J Thromb Haemost 2003; 1(4):625-631.
131. Remuzzi G. Is ADAMTS-13 deficiency specific for thrombotic thrombocytopenic purpura? No. J Thromb Haemost 2003; 1(4):632-634.
132. Plaimauer B, Scheiflinger F. Expression and characterization of recombinant human ADAMTS-13. Semin Hematol 2004; 41(1):24-33.